Fibrobiologics, INC DEF 14A proxy statements

FibroBiologics is holding a special meeting on September 17, 2026, to seek stockholder approval for the issuance of up to 8,163,266 shares of common stock upon warrant exercise, a move necessary to comply with Nasdaq Listing Rule 5635(d).

Fibrobiologics, Inc. announced its Annual Meeting of Stockholders will be held virtually on June 22, 2026, to elect a director, ratify auditor appointment, approve stock issuance, and adopt a new equity plan.

FibroBiologics, Inc. submitted definitive additional materials related to its proxy statement to the U.S. Securities and Exchange Commission.

FibroBiologics, Inc. calls a Special Meeting to approve a reverse stock split to maintain Nasdaq listing and ratify recent warrant issuances totaling over 22 million shares.

FibroBiologics, Inc. will hold a Special Meeting to vote on a reverse stock split to maintain Nasdaq listing and approve the issuance of shares underlying recent warrant offerings.

FibroBiologics, Inc. has filed a definitive proxy statement with the SEC.

FibroBiologics is asking stockholders to vote on proposals to increase authorized capital stock and approve the issuance of shares to Yorkville under a Standby Equity Purchase Agreement at the upcoming annual meeting.

FibroBiologics, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) in compliance with Section 14(a) of the Securities Exchange Act of 1934.

FibroBiologics is holding its annual meeting on August 27, 2024, to vote on director elections, auditor ratification, and amendments to its corporate charter.